Genagon: €500k

Case

9/14/22

Genagon Therapeutics and Mosaique Diagnostics receive a prestigious Eurostars grant to jointly undertake major steps towards the transition from the pre-clinical to clinical development of GEN209 - a drug candidate for triple-negative breast cancer (TNBC).

This will be a first-in-class monoclonal antibody-drug conjugate (ADC) targeting Clptm1, a novel molecular target expressed in solid tumors. GAEU Consulting supported the development of the Eurostars grant proposal.

Genagon Therapeutics full press release here: https://lnkd.in/dw8MUqTA

Tomasz Wąsik, MBA comments: “This life science project is an excellent example of a pre-clinical collaboration that meets all the criteria within Eurostars funding program – joint R&D, clear role of each partner and mutual commercial and scientific benefits at the end of the project. I would like to thank both teams for a very good cooperation in the application process”.

"I recommend GAEU Consulting as a trustworthy and competent advisor within Eurostars funding program. The funding we have received will help us to secure in vivo efficacy data, identify biomarkers for patient selection and treatment outcome follow-up. We will also design regulatory and toxicology programs allowing for a successful transition to clinical trials".

- Moa Fransson, CEO at Genagon Therapeutics

Eurostars is the largest international funding programme for SMEs that aim to collaborate on R&D projects that create innovative products, processes or services for commercialisation. The Eurostars project requires a consortium of at least two partners from two different Eureka network countries.